Rakuten Medical seeks FDA approval for "lightsaber" cancer treatment technology

Rakuten Medical, a Japanese biotech firm, is seeking to revolutionize cancer treatment in the United States with its innovative "lightsaber" technology.

The company's CEO, Minami Maeda, envisions surgeons putting down their scalpels and picking up a futuristic device that uses light to target cancer cells. This novel approach has garnered significant attention, with Maeda confident that it can make a significant impact on cancer treatment.

Rakuten Medical's technology was initially discovered by the National Cancer Institute, which stumbled upon its therapeutic potential while trying to use photoimmunotherapy for visualization purposes. The company has since developed a proprietary cancer drug called Akalux and a technology platform called Alluminox to administer photoimmunotherapy.

The Akalux drug works by binding to specific receptors on cancer cells and tagging them with light-activated dye, allowing for precise targeting of the disease. Rakuten Medical is now gearing up to submit its technology for FDA approval in 2028.

The treatment process involves applying red light to selectively destroy cancer cells that have been previously tagged using a unique dye.

This minimally invasive approach aims to preserve patients' quality of life while effectively treating the disease.

By doing so, Rakuten Medical's technology seeks to provide a more humane alternative to traditional cancer treatments.

Rakuten Medical has seen significant growth in Japan since its inception, with the company initially treating just 30 patients in its first year.

The number of patients being treated now stands at around 700 to 800 per year across approximately 200 hospitals.

This expansion is a testament to the effectiveness and appeal of the technology.

To overcome resistance from some doctors who were hesitant to adopt this new approach, Rakuten Medical has introduced an innovative business model.

Rakuten Medical's Japan branch has achieved profitability, despite the global company operating at a loss due to significant research expenses.

The biotech firm is now focusing on expanding into nearby markets that have already recognized the Akalux drug for regulatory approval in Japan. These countries include Taiwan, Macau, Singapore, Hong Kong, and Saudi Arabia.

By establishing itself in these regions, Rakuten Medical aims to create a gateway to larger potential markets, such as mainland China, and emerging economies in Southeast Asia, where its technology could provide significant benefits.